NeuroMetrix (NURO) Sees Wild Action After FDA 510 (k) clearance
Tweet
Share
E-mailGet Alerts NURO Hot Sheet
Join SI Premium – FREE
NeuroMetrix Inc. (Nasdaq: NURO) is off the highs, but still up 4 percent Monday, after FDA 510 (k) clearance for the company's Sensus nerve stimulator for pain relief. Link
Shares were as high as 29 percent earlier.
Shares were as high as 29 percent earlier.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
